# A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

> **NCT01039883** · PHASE1 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 40 (actual)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** Albaconazole tablet 400mg
- **DRUG:** Albaconazole 100mg capsules, then albaconazole 400mg tablet

## Key facts

- **NCT ID:** NCT01039883
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-23
- **Primary completion:** 2010-01-20
- **Final completion:** 2010-01-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039883, "A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01039883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*